Explore 3 Stock Ideas & Industry Insights Download Free Report

8082-737-676
Shopping Cart 0
countryflagUK
Login

Better Therapeutics Inc

Healthcare US BTTX

0.0001USD
0.00(0%)

Last update at 2025-01-29T20:00:00Z

Day Range

0.00010.0001
LowHigh

52 Week Range

0.00010.27
LowHigh

Fundamentals

  • Previous Close 0.0001
  • Market Cap0.00545M
  • Volume1256
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-29.17500M
  • Revenue TTM0.00000M
  • Revenue Per Share TTM-
  • Gross Profit TTM -0.67400M
  • Diluted EPS TTM-1.1

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Income before tax -39.75300M -40.48800M -6.23400M -5.78400M
Minority interest - - - -
Net income -39.76000M -40.33500M -6.38700M -5.79500M
Selling general administrative 14.84M 8.79M 2.46M 2.20M
Selling and marketing expenses 6.98M 2.34M 0.22M 0.41M
Gross profit - - -0.67400M -0.88000M
Reconciled depreciation 2.73M 1.62M 0.07M 0.07M
Ebit -40.99100M -32.17900M -6.32300M -5.77300M
Ebitda -38.26200M -30.56000M -6.24800M -5.70100M
Depreciation and amortization 2.73M 1.62M 0.07M 0.07M
Non operating income net other - - - -
Operating income -38.26200M -30.56000M -6.32300M -5.77300M
Other operating expenses 38.26M 30.56M 6.33M 5.79M
Interest expense 1.49M 0.18M 0.10M 0.01M
Tax provision 0.00700M -0.15300M 0.15M 0.00000M
Interest income - - - -
Net interest income -1.49100M -0.18500M -0.10000M -0.01100M
Extraordinary items - - - -
Non recurring - - - -
Other items - - - -
Income tax expense 0.00700M -0.15300M 0.15M 0.01M
Total revenue 0.00000M 0.00000M 0.00800M 0.02M
Total operating expenses 38.26M 30.56M 5.65M 4.89M
Cost of revenue - - 0.68M 0.90M
Total other income expense net -1.49100M -9.92800M 0.09M -0.01100M
Discontinued operations - - - -
Net income from continuing ops -39.76000M -40.33500M -6.38700M -5.78400M
Net income applicable to common shares -39.76000M -40.33500M -10.30700M -8.22600M
Preferred stock and other adjustments - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 22.94M 50.96M 6.39M 4.88M
Intangible assets 3.89M 5.08M 5.55M 3.27M
Earning assets - - - -
Other current assets 0.21M 0.28M 0.22M 0.23M
Total liab 23.84M 14.24M 13.14M 5.49M
Total stockholder equity -0.89900M 36.72M -6.75800M -0.60500M
Deferred long term liab - - 0.06M -
Other current liab 5.93M 3.21M 0.10M 0.15M
Common stock 0.00200M 0.00200M 0.00100M 0.21M
Capital stock 0.00200M 0.00200M 24.20M 24.42M
Retained earnings -111.50300M -71.74300M -31.40800M -25.02100M
Other liab - - 11.89M -
Good will - - - -
Other assets 0.49M 0.55M 0.28M 0.44M
Cash 15.74M 40.57M 0.12M 0.76M
Cash and equivalents - - - -
Total current liabilities 13.49M 4.73M 0.61M 0.49M
Current deferred revenue - - - -
Net debt -0.86000M -31.06100M 0.52M 4.24M
Short term debt 4.53M - - -
Short long term debt 4.53M - - -
Short long term debt total 14.88M 9.51M 0.64M 5.00M
Other stockholder equity 110.60M 108.46M 0.45M -
Property plant equipment 0.12M 0.08M 0.09M 0.18M
Total current assets 18.45M 45.25M 0.46M 0.99M
Long term investments - - - -
Net tangible assets -4.78700M 31.64M -36.51700M -28.07600M
Short term investments - - - -
Net receivables - 0.28M 0.22M -
Long term debt 10.35M 9.51M 0.64M 5.00M
Inventory - - - -
Accounts payable 3.04M 1.52M 0.51M 0.34M
Total permanent equity - - - -
Noncontrolling interest in consolidated entity - - - -
Temporary equity redeemable noncontrolling interests - - - -
Accumulated other comprehensive income - - - -
Additional paid in capital - - - -
Common stock total equity - - - -
Preferred stock total equity - - - -
Retained earnings total equity - - - -
Treasury stock - - - -
Accumulated amortization - - - -
Non currrent assets other 0.49M 0.55M 0.28M 0.44M
Deferred long term asset charges - - - -
Non current assets total 4.50M 5.71M 5.92M 3.89M
Capital lease obligations - - - -
Long term debt total - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Investments -1.18000M -1.07100M -2.30500M -2.73600M
Change to liabilities 1.51M 1.01M 0.18M -0.06800M
Total cashflows from investing activities -1.18000M -1.07100M -2.30500M -2.73600M
Net borrowings 5.00M 28.68M 7.45M 5.00M
Total cash from financing activities 5.28M 72.33M 7.45M 8.70M
Change to operating activities 4.76M -3.34800M 0.12M -0.52100M
Net income -39.76000M -40.33500M -6.38700M -5.78400M
Change in cash -24.82600M 40.44M -0.63400M -0.25300M
Begin period cash flow 40.57M 0.12M 0.76M 1.01M
End period cash flow 15.74M 40.57M 0.12M 0.76M
Total cash from operating activities -28.93000M -30.81800M -5.77400M -6.21700M
Issuance of capital stock - - 0.00000M 3.70M
Depreciation 2.73M 1.62M 0.07M 0.07M
Other cashflows from investing activities - - - -
Dividends paid - - - -
Change to inventory - - - -
Change to account receivables - - - -
Sale purchase of stock - - - -
Other cashflows from financing activities 5.03M 87.20M 7.45M -2.73600M
Change to netincome 1.83M 10.24M 0.23M 0.08M
Capital expenditures 1.18M 1.07M 2.31M 2.74M
Change receivables - - - -
Cash flows other operating - - - -
Exchange rate changes - - - -
Cash and cash equivalents changes - - - -
Change in working capital 6.27M -2.33900M 0.31M -0.58900M
Stock based compensation 1.82M 0.65M 0.23M 0.08M
Other non cash items 0.00900M 9.74M -0.15300M -
Free cash flow -30.11000M -31.88900M -8.07900M -8.95300M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
BTTX
Better Therapeutics Inc		 - -% 0.0001 - - 49559.41 2.29 74299.06 -0.4641
NVO
Novo Nordisk A/S		 -0.92 2.14% 42.00 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 -0.75 1.73% 42.50 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 3.25 0.76% 428.34 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 16.03 2.66% 618.95 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Better Therapeutics, Inc., a prescription digital therapeutics company, develops a form of cognitive behavioral therapy to address the causes of cardiometabolic diseases. The company's lead product candidate is BT-001, an investigational PDT platform to treat type 2 diabetes. It also develops software-based prescription digital therapeutics platform candidates for treating diabetes, heart disease, and other cardiometabolic conditions. In addition, the company's clinical development candidates are intended to treat cardiometabolic diseases, including type 2 diabetes, hypertension, hyperlipidemia, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, and chronic kidney disease. Its product pipeline also includes BT-002, which intends glycemic control for hypertension; BT-003 to reduce LDL cholesterol in patients with hyperlipidemia; and BT-004, which intends to explore the impact of treatment on liver health in patients with non-alcoholic steatohepatitis/non-alcoholic fatty liver disease. The company was founded in 2015 and is headquartered in San Francisco, California.

Better Therapeutics Inc

548 Market Street, San Francisco, CA, United States, 94104

Key Executives

Name Title Year Born
Mr. David P. Perry M.B.A. Co-Founder & Exec. Chairman 1968
Dr. Mark A. Berman M.D. Chief Medical Officer 1975
Ms. Kristin Wynholds Chief Product Officer 1972
Mr. Frank L. Karbe CEO, Pres & Director 1968
Mr. Mark Heinen Head of Fin. & Interim CFO 1969
Mr. Andres Camacho Sr. VP of Technology & Head of Engineering NA
Mr. Thiago Licias De Oliveira Chief People Officer NA
Ms. Diane Gomez-Thinnes Chief Commercial Officer NA
Mr. David P. Perry M.B.A. Co-Founder & Executive Chairman 1968
Mr. Frank L. Karbe CEO, Interim CFO, President & Director 1968

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

We use cookies to help us improve, promote, and protect our services. By continuing to use this site, we assume you consent to our Cookies Policy. For more information, read our Privacy Policy and Terms and Conditions